1. Indianapolis;Basaglar [prescribing information],2016
2. Truven Health Analytics. Micromedex Solutions [Internet]. Available from http://www.micromedexsolutions.com/micromedex2/librarian/CS/8685A3/ND_PR/evidencexpert/ND_P/evidencexpert/DUPLICATIONSHIELDSYNC/2827FF/ND_PG/evidencexpert/ND_B/evidencexpert/ND_AppProduct/evidencexpert/ND_T/evidencexpert/PFActionId/redbook.FindRedBook?navitem=topRedBook&isToolPage=true. Accessed 1 March 2017
3. Biosimilars and new insulin versions;Peters;Endocr Pract,2015
4. U.S. Food and Drug Administration. FDA approves Basaglar, the first “follow-on” insulin glargine product to treat diabetes. Available from https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm477734.htm. Accessed 1 March 2017
5. Efficacy and safety of LY2963016 insulin glargine compared with insulin glargine (Lantus®) in patients with type 1 diabetes in a randomised controlled trial (the ELEMENT 1 study);Blevins;Diabetes Obes Metab,2015